Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Phase 4

Withdrawn

Conditions: Ocular Hypertension

Interventions: Drug: Latanoprostene Bunod
Drug: Placebo

First Posted Date: 2019-10-25

Last Posted Date: 2024-03-04

Lead Sponsor: Bausch & Lomb Incorporated

Registration Number: NCT04140279

Locations: 🇺🇸
Bausch Site 001, Rochester, Minnesota, United States

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Phase 3

Completed

Conditions: Dry Eye Disease (DED)

Interventions: Drug: NOV03
Drug: Placebo

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-23

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 599

Registration Number: NCT04139798

Locations: 🇺🇸
Bausch Site 112, Indianapolis, Indiana, United States
🇺🇸
103, Torrance, California, United States
🇺🇸
Bausch Site 115, Jacksonville, Florida, United States

and more 26 locations

A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

Not Applicable

Completed

Conditions: Myopic Astigmatism
Myopia

Interventions: Device: Technolas® TENEO 317 Model 2

First Posted Date: 2019-10-01

Last Posted Date: 2024-06-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 168

Registration Number: NCT04111757

Locations: 🇺🇸
Bausch Site 108, Omaha, Nebraska, United States
🇺🇸
Bausch Site 109, Sioux Falls, South Dakota, United States
🇺🇸
Bausch Site 106, Portsmouth, New Hampshire, United States

and more 7 locations

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Phase 1

Completed

Conditions: Glaucoma
Open Angle or Ocular Hypertension

Interventions: Drug: brinzolamide 1% ophthalmic suspension
Drug: Azopt 1%

First Posted Date: 2019-04-01

Last Posted Date: 2023-05-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 637

Registration Number: NCT03896633

Locations: 🇺🇸
Various, Bridgewater, New Jersey, United States

A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: ABT12 Multi-Purpose Solution
Device: COMPLETE Multi-Purpose Solution
Device: Sensitive Eyes® Rewetting Drops

First Posted Date: 2019-04-01

Last Posted Date: 2023-03-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 252

Registration Number: NCT03897751

Locations: 🇺🇸
Bausch Site 14, Vestal, New York, United States
🇺🇸
Bausch Site 17, Brentwood, Tennessee, United States
🇺🇸
Bausch Site 2, San Diego, California, United States

and more 14 locations

A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: Alden Optical HP Sphere Contact Lens
Device: Custom Samfilcon B Contact Lenses
Device: ReNu MultiPlus Lubricating and Rewetting Drops
Device: Biotrue Multi-Purpose Solution

First Posted Date: 2019-04-01

Last Posted Date: 2022-11-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 84

Registration Number: NCT03897712

Locations: 🇺🇸
Bausch Site 5, Warrensburg, Missouri, United States
🇺🇸
Bausch Site 1, San Francisco, California, United States
🇺🇸
Bausch Site 6, Vestal, New York, United States

and more 4 locations

Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism

Not Applicable

Completed

Conditions: Astigmatism

Interventions: Device: Test
Device: Control

First Posted Date: 2018-09-24

Last Posted Date: 2021-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 242

Registration Number: NCT03681808

Locations: 🇺🇸
Bausch Site 117, Irvine, California, United States
🇺🇸
Bausch Site 102, Jacksonville, Florida, United States
🇺🇸
Bausch Site 108, San Jose, California, United States

and more 10 locations

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: enVista MX60E
Device: enVista MX60EF

First Posted Date: 2018-07-27

Last Posted Date: 2024-12-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 501

Registration Number: NCT03603600

Locations: 🇺🇸
Bausch Site 118, Las Vegas, Nevada, United States
🇺🇸
Bausch Site 121, Sioux Falls, South Dakota, United States
🇺🇸
Bausch Site 119, Birmingham, Mississippi, United States

and more 20 locations

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: Bausch & Lomb DVisc40
Device: Alcon VISCOAT®

First Posted Date: 2018-04-30

Last Posted Date: 2021-10-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 372

Registration Number: NCT03511638

Locations: 🇺🇸
Valeant Site 01, San Diego, California, United States

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: EM-100
Drug: Zaditor®
Drug: Vehicle

First Posted Date: 2018-04-06

Last Posted Date: 2023-06-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 65

Registration Number: NCT03489941

Locations: 🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy